Association of FcgR2a, but not FcgR3a, with inflammatory bowel diseases across three Caucasian populations

Inflammatory Bowel Diseases

Volumn 16, Issue 12, 2010, Pages 2080-2089

  Weersma, Rinse K ^a   Crusius, J Bart A ^b   Roberts, Rebecca L ^c   Koeleman, Bobby P C ^e   Palomino Morales, Rogelio ^d   Wolfkamp, Simone ^f   Hollis Moffatt, Jade E ^g   Festen, Eleonora A M ^a   Meisneris, Sander ^f   Heijmans, Roel ^b   Noble, Colin L ^h   Gearry, Richard B ^g,h   Barclay, Murrary L ⁱ   Gómez Garcia, María ^j   Lopez Nevot, Miguel A ^j   Nieto, Antonio ^k   Rodrigo, Luis ^i,l   Radstake, Timothy R D J ^m   Van Bodegraven, Adriaan A ^b   Wijmenga, Cisca ^a   Merriman, Tony R ^g   Stokkers, Pieter C F ^f   Peãa, A Salvador ^b   Martín, Javier ^c   Alizadeh, Behrooz Z ^a,e   more..

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF OTAGO   (New Zealand)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

ⁱ CHRISTCHURCH HOSPITAL   (New Zealand)

^j HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^k HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^l HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^m RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Crohn's disease; FcgR2a; FcgR3a; genome wide association study; ulcerative colitis

Indexed keywords

CD16 ANTIGEN; FC RECEPTOR IIA;

ARTICLE; CAUCASIAN; CLINICAL TRIAL; CLUSTER ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NETHERLANDS; NEW ZEALAND; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR GENE; SPAIN; ULCERATIVE COLITIS;

CASE-CONTROL STUDIES; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; NETHERLANDS; NEW ZEALAND; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IGG; SPAIN;

EID: 78649562752     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21342     Document Type: Article

References (72)

1. Mathew CG,. New links to the pathogenesis of Crohn disease provided by genome-wide association scans. Nat Rev Genet. 2008; 9: 9-14.
2. Jewell DP,. New patients, new lessons, new thinking in inflammatory bowel disease: World Congress of Gastroenterology Symposium, Montreal, Canada, September 2005. Colorectal Dis. 2006; 8: 1-2.
3. Cummings JR, Jewell DP,. Clinical implications of inflammatory bowel disease genetics on phenotype. Inflamm Bowel Dis. 2005; 11: 56-61.
4. Xavier RJ, Rioux JD,. Genome-wide association studies: a new window into immune-mediated diseases. Nat Rev Immunol. 2008; 8: 631-643.
5. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet. 2007; 39: 830-832.
6. Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007; 39: 207-211. (Pubitemid 46184351)
7. Weersma RK, Zhernakova A, Nolte IM, et al. ATG16L1 and IL23R are associated with inflammatory bowel diseases but not with celiac disease in the Netherlands. Am J Gastroenterol. 2008; 103: 621-627.
8. Palomino-Morales RJ, Oliver J, Gomez-Garcia M, et al. Association of ATG16L1 and IRGM genes polymorphisms with inflammatory bowel disease: a meta-analysis approach. Genes Immun. 2009; 10: 356-364.
9. Dijstelbloem HM, van de Winkel JG, Kallenberg CG,. Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol. 2001; 22: 510-516.
10. Takai T,. Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol. 2005; 25: 1-18.
11. Bredius RG, Fijen CA, De Haas M, et al. Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes. Immunology. 1994; 83: 624-630.
12. Corper AL, Sohi MK, Bonagura VR, et al. Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nat Struct Biol. 1997; 4: 374-381.
13. Adams RJ, Heazlewood SP, Gilshenan KS, et al. IgG antibodies against common gut bacteria are more diagnostic for Crohn's disease than IgG against mannan or flagellin. Am J Gastroenterol. 2008; 103: 386-396.
14. Kemler BJ, Alpert E,. Inflammatory bowel disease associated circulating immune complexes. Gut. 1980; 21: 195-201.
15. Shafir M, Martinelli G, Bekesi JG, et al. Immunoglobulins (Ig) in circulating immune complexes (CIC) in cancer and inflammatory bowel disease (IBD). Eur J Surg Oncol. 1986; 12: 351-357.
16. Alizadeh BZ, Valdigem G, Coenen MJ, et al. Association analysis of functional variants of the FcgRIIa and FcgRIIIa genes with type 1 diabetes, celiac disease and rheumatoid arthritis. Hum Mol Genet. 2007; 16: 2552-2559.
17. Karassa FB, Trikalinos TA, Ioannidis JP,. Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum. 2002; 46: 1563-1571.
18. Karassa FB, Trikalinos TA, Ioannidis JP,. The role of FcgammaRIIA and IIIA polymorphisms in autoimmune diseases. Biomed Pharmacother. 2004; 58: 286-291.
19. Karassa FB, Bijl M, Davies KA, et al. Role of the Fcgamma receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis. Arthritis Rheum. 2003; 48: 1930-1938.
20. Harley JB, Alarcon-Riquelme ME, Criswell LA, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008; 40: 204-210.
21. Trikalinos TA, Karassa FB, Ioannidis JP,. Meta-analysis of the association between low-affinity Fcgamma receptor gene polymorphisms and hematologic and autoimmune disease. Blood. 2001; 98: 1634-1635.
22. van der Pol WL, van den Berg LH, Scheepers RH, et al. IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barre syndrome. Neurology. 2000; 54: 1661-1665.
23. Dijstelbloem HM, Scheepers RH, Oost WW, et al. Fcgamma receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse. Arthritis Rheum. 1999; 42: 1823-1827.
24. Chu ZT, Tsuchiya N, Kyogoku C, et al. Association of Fcgamma receptor IIb polymorphism with susceptibility to systemic lupus erythematosus in Chinese: a common susceptibility gene in the Asian populations. Tissue Antigens. 2004; 63: 21-27.
25. Zuniga R, Ng S, Peterson MG, et al. Low-binding alleles of Fcgamma receptor types IIA and IIIA are inherited independently and are associated with systemic lupus erythematosus in Hispanic patients. Arthritis Rheum. 2001; 44: 361-367.
26. Raychaudhuri S, Thomson BP, Remmers EF, et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet. 2009; 41: 1313-1318.
27. Karassa FB, Trikalinos TA, Ioannidis JP,. The Fc gamma RIIIA-F158 allele is a risk factor for the development of lupus nephritis: a meta-analysis. Kidney Int. 2003; 63: 1475-1482.
28. Forabosco P, Gorman JD, Cleveland C, et al. Meta-analysis of genome-wide linkage studies of systemic lupus erythematosus. Genes Immun. 2006; 7: 609-614.
29. Edberg JC, Langefeld CD, Wu J, et al. Genetic linkage and association of Fcgamma receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus. Arthritis Rheum. 2002; 46: 2132-2140.
30. Kastbom A, Ahmadi A, Soderkvist P, et al. The 158V polymorphism of Fc gamma receptor type IIIA in early rheumatoid arthritis: increased susceptibility and severity in male patients (the Swedish TIRA project). Rheumatology. 2005; 44: 1294-1298.
31. Noble CL, Abbas AR, Cornelius J, et al. Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis. Gut. 2008; 57: 1398-1405.
32. Asano K, Matsushita T, Umeno J, et al. A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. Nat Genet. 2009; 41: 1325-1329.
33. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008; 40: 955-962.
34. Latiano A, Palmieri O, Valvano MR, et al. Evaluating the role of the genetic variations of PTPN22, NFKB1, and FcGRIIIA genes in inflammatory bowel disease: a meta-analysis. Inflamm Bowel Dis. 2007; 13: 1212-1219.
35. van Bodegraven AA, Curley CR, Hunt KA, et al. Genetic variation in myosin IXB is associated with ulcerative colitis. Gastroenterology. 2006; 131: 1768-1774.
36. Hadithi M, Cazemier M, Meijer GA, et al. Retrospective analysis of old-age colitis in the Dutch inflammatory bowel disease population. World J Gastroenterol. 2008; 14: 3183-3187.
37. Stokkers PC, Huibregtse K Jr, Leegwater AC, et al. Analysis of a positional candidate gene for inflammatory bowel disease: NRAMP2. Inflamm Bowel Dis. 2000; 6: 92-98.
38. de Ridder L, Weersma RK, Dijkstra G, et al. Genetic susceptibility has a more important role in pediatric-onset Crohn's disease than in adult-onset Crohn's disease. Inflamm Bowel Dis. 2007; 13: 1083-1092.
39. Nunez C, Oliver J, Mendoza JL, et al. CD209 in inflammatory bowel disease: a case-control study in the Spanish population. BMC Med Genet. 2007; 8: 75.
40. Roberts RL, Gearry RB, Hollis-Moffatt JE, et al. IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease. Am J Gastroenterol. 2007; 102: 2754-2761.
41. Gearry RB, Richardson A, Frampton CM, et al. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis. 2006; 12: 936-943.
42. Simkins HM, Merriman ME, Highton J, et al. Association of the PTPN22 locus with rheumatoid arthritis in a New Zealand Caucasian cohort. Arthritis Rheum. 2005; 52: 2222-2225.
43. Lennard-Jones JE,. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989; 170: 2-6.
44. Salmon JE, Edberg JC, Brogle NL, et al. Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function. J Clin Invest. 1992; 89: 1274-1281.
45. Bredius RG, Derkx BH, Fijen CA, et al. Fc gamma receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children. J Infect Dis. 1994; 170: 848-853.
46. Salmon JE, Edberg JC, Kimberly RP,. Fc gamma receptor III on human neutrophils. Allelic variants have functionally distinct capacities. J Clin Invest. 1990; 85: 1287-1295.
47. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997; 100: 1059-1070.
48. Fisher SA, Tremelling M, Anderson CA, et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet. 2008; 40: 710-712.
49. Parkes M, Jewell D,. Ulcerative colitis and Crohns disease: molecular genetics and clinical implications. Expert Rev Mol Med. 2001; 2001: 1-18.
50. Agresti A,. Categorical data analysis. New York: John Wiley & Sons; 1990.
51. Cordell HJ, Todd JA, Hill NJ, et al. Statistical modeling of interlocus interactions in a complex disease: rejection of the multiplicative model of epistasis in type 1 diabetes. Genetics. 2001; 158: 357-367.
52. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007; 81: 559-575.
53. Oliver J, Marquez A, Gomez-Garcia M, et al. Association of the macrophage migration inhibitory factor gene polymorphisms with inflammatory bowel disease. Gut. 2007; 56: 150-151.
54. Morgan AW, Barrett JH, Griffiths B, et al. Analysis of Fcgamma receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B. Arthritis Res Ther. 2006; 8: 5.
55. Morgan AW, Robinson JI, Barrett JH, et al. Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. Arthritis Res Ther. 2006; 8: 109.
56. Yuan H, Pan HF, Li LH, et al. Meta analysis on the association between FcgammaRIIa-R/H131 polymorphisms and systemic lupus erythematosus. Mol Biol Rep. 2009; 36: 1053-1058.
57. Imielinski M, Baldassano RN, Griffiths A, et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet. 2009; 41: 1335-1340.
58. Hao K,. Genome-wide selection of tag SNPs using multiple-marker correlation. Bioinformatics. 2007; 23: 3178-3184.
59. Barrett JC, Lee JC, Lees CW, et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet. 2009; 41: 1330-1334.
60. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007; 447: 661-678.
61. Lee YH, Rho YH, Choi SJ, et al. The PTPN22 C1858T functional polymorphism and autoimmune diseases-a meta-analysis. Rheumatology. 2007; 46: 49-56.
62. Martin MC, Oliver J, Urcelay E, et al. The functional genetic variation in the PTPN22 gene has a negligible effect on the susceptibility to develop inflammatory bowel disease. Tissue Antigens. 2005; 66: 314-317.
63. Matsumoto I, Zhang H, Muraki Y, et al. A functional variant of Fcgamma receptor IIIA is associated with rheumatoid arthritis in individuals who are positive for anti-glucose-6-phosphate isomerase antibodies. Arthritis Res Ther. 2005; 7: 1183-1188.
64. Chatenoud L,. CD3 antibody treatment stimulates the functional capability of regulatory T cells. Novartis Found Symp. 2003; 252: 279-290.
65. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005; 352: 2598-2608. (Pubitemid 41007846)
66. Sandborn WJ,. Clinical perspectives in Crohn's disease. Moving forward with anti-TNF-alpha therapy: current needs and future treatments. Rev Gastroenterol Disord. 2007; 7: 23-35.
67. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med. 2004; 351: 2069-2079.
68. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003; 348: 24-32.
69. Plevy S, Salzberg B, Van Assche G, et al. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology. 2007; 133: 1414-1422.
70. Kabelitz D, Wesch D, Oberg HH,. Regulation of regulatory T cells: role of dendritic cells and toll-like receptors. Crit Rev Immunol. 2006; 26: 291-306.
71. Himmel ME, Hardenberg G, Piccirillo CA, et al. The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease. Immunology. 2008; 125: 145-153.
72. Li X, Conklin L, Alex P,. New serological biomarkers of inflammatory bowel disease. World J Gastroenterol. 2008; 14: 5115-5124.